Bronchiectasis is a chronic condition of the respiratory system, in which there is abnormal widening of the airways due to an initial damaging factor. This in turn reduces the ability of the bronchi ...

The FDA has approved Insmed’s brensocatib (Brinsupri)— an oral small-molecule inhibitor of dipeptidyl peptidase 1 (DPP1) — for non-cystic fibrosis bronchiectasis. It is the first drug specifically ...

The Dominion Post’s recent cover story (9 February) pays tribute to the tragic passing of beautiful young toddler Ataahua, who died of bronchiectasis just shy of three years of age. Bronchiectasis is ...

Please provide your email address to receive an email when new articles are posted on . Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

The FDA is weighing the regulatory fate of Insmed’s DPP1 inhibitor brensocatib for bronchiectasis. An approval for the oral small-molecule protease inhibitor would provide a much-needed targeted ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...

ORLANDO, FL / ACCESS Newswire / August 18, 2025 / The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket ...

It’s easy to blame swollen fingers on heat or a salty meal — but sometimes, your body might be alerting you to something far ...

Insmed plans to file a New Drug Application with the Food and Drug Administration in the fourth quarter of 2024. Treatment with brensocatib reduced the frequency of pulmonary exacerbations in patients ...

The US saw several new and expanded FDA indications this year. The top 5 most-read FDA approvals on AJMC.com included 4 novel ...

The designation was supported by data from the multicenter, double-blind, placebo-controlled phase 3 PROMIS-I study. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...